Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

• ClinicalTrials.gov Identifier: NCT04418414
• Recruitment Status: Not yet recruiting
• First Posted: June 5, 2020
• Last Update Posted: February 20, 2024
• Sponsor: Expression Therapeutics, LLC
• Information provided by (Responsible Party): Expression Therapeutics, LLC

Tracking Information

• First Submitted Date: May 28, 2020
• First Posted Date: June 5, 2020
• Last Update Posted Date: February 20, 2024
• Estimated Study Start Date: September 1, 2024
• Estimated Primary Completion Date: August 2029 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: June 3, 2020)

• Number of study participants experiencing serious adverse events (SAEs) following treatment through 12 weeks. [ Time Frame: 12 weeks ]
  As assessed by physical examination, vital signs, clinical labs, and FVIII inhibitor levels (Bethesda assay). Serious adverse event (SAE) is an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly.
• Severity of serious adverse events following administration of CD68-ET3-LV CD34+ as assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) Version 5.0. [ Time Frame: 12 weeks ]
  Serious adverse events
• Duration of the serious adverse events following administration of CD68-ET3-LV CD34+. [ Time Frame: 12 weeks ]
  As assessed by stop and end dates of the SAEs

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: September 25, 2020)

• Time to absolute neutrophil count (ANC) recovery. [ Time Frame: Measured up to 5 years. ]
  Time to ANC recovery (the first day a neutrophil count is >0.5 x 109/L (>500/µL) on three consecutive days) following busulfan/ anti-thymocyte globulin conditioning and infusion of autologous CD34+ hematopoietic stem and progenitor cells (HSPC) transduced with CD68-ET3-LV.
• Time to platelet recovery. [ Time Frame: Measured up to 5 years. ]
  Time to platelet recovery (the first day a platelet count is > 50,000/µL on three consecutive days without platelet transfusions during the prior 7 days) following infusion of autologous CD34+ cells transduced with CD68-ET3-LV.
• Anti-human factor VIII inhibitor titer [ Time Frame: Measured up to 5 years. ]
  Assessed via Bethesda assay
• Immune response to ET3 as measured by modified Bethesda assay incorporating ET3i spiked into fVIII-deficient plasma [ Time Frame: Measured up to 5 years. ]
  Immune response to ET3
• Vector copy number of circulating genetically modified cells as determined by real time PCR [ Time Frame: Measured up to 5 years. ]
  Vector copy number determined via real time PCR
• Clonality of circulating genetically modified cells as determined by LAM-PCR and insertion site analysis using DNA sequencing of LAM-PCR products [ Time Frame: Measured up to 5 years. ]
  Clonality assessment via LAM-PCR
• Survival of autologous HSCT CD68-ET3-LV gene therapy. [ Time Frame: Up to 12 weeks following treatment ]
  Survival among subjects who were treated with autologous HSCT with CD68-ET3-LV CD34+.

Original Secondary Outcome Measures (submitted: June 3, 2020)

• Survival of autologous HSCT CD68-ET3-LV gene therapy. [ Time Frame: Up to 12 weeks following treatment ]
  Survival among subjects who were treated with autologous HSCT with CD68-ET3-LV CD34+.
• Immune response to ET3 as measured by modified Bethesda assay incorporating ET3i spiked into fVIII-deficient plasma [ Time Frame: Through long term follow-up (up to 15 years) ]
  Immune response to ET3
• Time to absolute neutrophil count (ANC) recovery. [ Time Frame: Measured through study completion (up to 15 years). ]
  Time to ANC recovery (the first day a neutrophil count is >0.5 x 109/L (>500/µL) on three consecutive days) following busulfan/ anti-thymocyte globulin conditioning and infusion of autologous CD34+ hematopoietic stem and progenitor cells (HSPC) transduced with CD68-ET3-LV.
• Time to platelet recovery. [ Time Frame: Measured through study completion (up to 15 years). ]
  Time to platelet recovery (the first day a platelet count is > 50,000/µL on three consecutive days without platelet transfusions during the prior 7 days) following busulfan/ anti-thymocyte globulin conditioning and infusion of autologous CD34+ cells transduced with CD68-ET3-LV.
• Vector copy number of circulating genetically modified cells as determined by real time PCR [ Time Frame: Through long term follow-up (up to 15 years) ]
  Vector copy number determined via real time PCR
• Clonality of circulating genetically modified cells as determined by LAM-PCR through long term follow-up (up to 15 years) [ Time Frame: Through long term follow-up (up to 15 years) ]
  Clonality assessment via LAM-PCR

Current Other Pre-specified Outcome Measures (submitted: September 25, 2020)

• Factor VIII (fVIII) Activity Level following autologous HSCT [ Time Frame: Measured up to 5 years. ]
  Measured by circulating plasma FVIII activity levels and detection of factor VIII and ET3 antigen
• Annualized bleed rate (ABR) assessed by number of bleeding episodes and in comparison to before gene therapy. [ Time Frame: Measured through long term follow-up (up to 15 years). ]
  To evaluate the impact of autologous HSCT with CD68-ET3-LV CD34+ on annualized bleed rate.
• Consumption of exogenous Factor VIII by evaluating historical clotting factor usage versus usage post-transplant. [ Time Frame: Historical data from prior to study enrollment versus post-transplant (up to 15 years). ]
  The percentage of participants with a reduction in exogenous FVIII consumption post-transplant compared with historical consumption.

Original Other Pre-specified Outcome Measures (submitted: June 3, 2020)

• Plasma Factor VIII (fVIII) Activity Level based on one-stage clotting and chromogenic assays. [ Time Frame: From screening visit to long term follow-up (up to 15 years) ]
  Circulating plasma FVIII activity level
• Annualized bleed rate (ABR) assessed by number of bleeding episodes and in comparison to before gene therapy. [ Time Frame: Measured through long term follow-up (up to 15 years). ]
  To evaluate the impact of autologous HSCT with CD68-ET3-LV CD34+ on annualized bleed rate.
• Consumption of exogenous Factor VIII by evaluating historical clotting factor usage versus usage post-transplant. [ Time Frame: Historical data from prior to study enrollment versus post-transplant (up to 15 years). ]
  The percentage of participants with a reduction in exogenous FVIII consumption post-transplant compared with historical consumption.
• Number of participants with evidence of engraftment of transduced CD68-ET3-LV CD34+ cells (genetically modified cells). [ Time Frame: From screening visit to long term follow-up (up to 15 years). ]
  As measured by the presence of ET3 transgene in blood.

Descriptive Information

• Brief Title: Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A
• Official Title: ET3-201: Phase 1 Study of Hematopoietic Stem Cell Transplantation (HSCT) Gene Therapy Incorporating a Lentiviral Vector (LV) Encoding a High Expressing Factor VIII Transgene for Treatment of Severe Hemophilia A
• Brief Summary: This is a first-in-human, non-randomized, open label, single treatment, Phase 1 study in approximately 7 patients with severe hemophilia A. The study will evaluate gene therapy by transplantation of autologous CD34+ hematopoietic stem cells transduced ex vivo with the CD68-ET3 lentiviral vector.
• Detailed Description: Eligible subjects will undergo CD34+ hematopoietic stem cell collection. These cells will be transduced ex vivo with CD68-ET3 lentiviral vector and subsequently, following a conditioning regimen of busulfan and anti-thymocyte globulin, the transduced cells will be infused to patients. After completion of study treatment, patients are followed up periodically for up to 15 years.
• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Hemophilia A

Intervention

• Drug: Gene therapy
  CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
  Other Name: CD68-ET3-LV CD34+
• Other: Biological
  G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.

Study Arms

Experimental: Autologous HSCT CD68-ET3-LV gene therapy

G-CSF/Plerixafor mobilization and apheresis will be used for collection of hematopoietic stem cells and subjects will receive transplantation of autologous CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector encoding the human factor VIII gene.

Interventions:

• Drug: Gene therapy
• Other: Biological

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Not yet recruiting
• Estimated Enrollment (submitted: June 3, 2020): 7
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: August 2039
• Estimated Primary Completion Date: August 2029 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Able to provide informed consent for the protocol approved by the Institutional Review Board.
2. Male subjects who are >= 18 years of age.
3. Diagnosis of severe hemophilia A (<1 IU/dL factor VIII activity) based on one-stage coagulation assay.
4. Documented history of more than 150 days of factor VIII treatment.
5. Average of at least 4 bleeds requiring treatment per year over the prior three years, or at least 4 bleeds per year during the 3 years preceding the initiation of prophylaxis, or evidence of joint damage (knee, elbow or ankle) on physical or radiographic examination thought to be related to hemophilia.
6. Performance status (Karnofsky score) of at least 70.
7. Willingness to use effective barrier contraception or limit sexual intercourse to postmenopausal, surgically sterilized, or contraception-practicing partners, for 12 weeks (3 months) after transplantation.
8. Willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

1. History of spontaneous central nervous system bleeding within the last 5 years.

2. Significant functional deficits in major organs which would interfere with successful outcome following autologous stem cell transplant, the following guidelines will be utilized:

   1. Cardiac: There should be no evidence of significant cardiac dysfunction (resting left ventricular ejection fraction of < 50%) and no marked cardiomegaly. There should not be uncontrollable hypertension.
   2. Renal: GFR < 60 mL/min/1.73m2 per local institutional standard such as CKD-EPI creatinine equation or equivalent.
   3. Hepatic: There should be no evidence of hepatic dysfunction which is defined as a serum total bilirubin of > 1.5 mg/dL and AST/ALT > 3X the upper limit of normal.
   4. Hematologic: Absolute neutrophil counts (ANC) <1000/ µL or platelets counts < 150,000/µL.
   5. Pulmonary function with a corrected carbon monoxide diffusing capacity (cDLCO) < 50% predicted.
3. History of a fVIII inhibitor (> 0.4 Bethesda Units/mL) including at least 2 measurements done at least a week apart or any single titer > 5 BU/mL.
4. Subjects who have had prior cellular based therapy or gene editing/ gene therapy including a previous stem cell transplant.
5. Subjects with any evidence of active infection or any immunosuppressive disorder, including currently detectable HIV viral load
6. Subjects who are RPR, anti-HTLV-1 and II antibody, CMV PCR, VZV antibody and HSV PCR positive at screening.
7. Subjects who have allergic reactions or hypersensitivity to any of the drugs used in the study (i.e., anti-thymocyte globulin, plerixafor, G-CSF, busulfan, levetiracetam) or to the constituents of the investigational product formulation.
8. Evidence of hepatitis B active infection or chronic carrier based on a positive Hepatitis B DNA testing at screening.
9. Positive (detectable viral load per local institutional standard) for the presence of Hepatitis C virus (HCV). Subjects who are positive for anti-HCV antibody are eligible as long as they have a negative undetectable HCV viral load at screening.
10. Subjects diagnosed with any history of clinically relevant coagulation or bleeding disorder other than hemophilia A.
11. Use of medication(s) that can affect hemostasis (e.g. aspirin, ibuprofen and non-COX-2 selective non-steroid anti-inflammatory drugs).
12. Subjects with a history of a malignancy (except surgically resected non-melanoma skin cancer) or subjects with a family history of a known cancer syndrome in a first degree relative.
13. Planned surgery within 6 months of enrollment (other than study procedures).
14. Treatment with any live vaccines or systemic immunosuppressive agents, not including corticosteroids within 30 days before CD68-ET3-LV CD34+ infusion.
15. Treatment with any investigational product within 30 days or 5 half-lives of the investigational product (whichever is longer) prior to enrollment.
16. History of autoimmune disease (e.g., inflammatory bowel disease, systemic lupus erythematosus, vasculitis).
17. Concurrent enrollment in another clinical study, which might interfere with the requirements of this study or have the potential to impact the evaluation of safety and efficacy of CD68-ET3-LV CD34+- unless it is a non-interventional observational study.
18. Any condition in the opinion of the Study Investigators that will negatively impact the subject's ability to safely undergo an autologous stem cell transplant.
19. Any reason in the opinion of the Study Investigators that will negatively impact the subject's ability to complete the clinical trial per the trial protocol.

Sex/Gender

• Sexes Eligible for Study: Male

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Study Coordinator; 404-850-0123; clinicaltrials@expressiontherapeutics.com

• Listed Location Countries: Not Provided

Administrative Information

• NCT Number: NCT04418414
• Other Study ID Numbers: ET3-201
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Expression Therapeutics, LLC
• Original Responsible Party: Same as current
• Current Study Sponsor: Expression Therapeutics, LLC
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Expression Therapeutics, LLC
• Verification Date: February 2024